Angiochem Inc. Patent applications |
Patent application number | Title | Published |
20150147310 | TARGETED ENZYME COMPOUNDS AND USES THEREOF - The present invention is related to a compound that includes (a) α-L-iduronidase (IDUA), fragment, or analog thereof and (b) a targeting moiety, for example, where compound is a fusion protein including IDUA and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating mucopolysaccharidosis type I (MPS-I) using such compounds. | 05-28-2015 |
20150037311 | TARGETED LYSOSOMAL ENZYME COMPOUNDS - The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds. | 02-05-2015 |
20120277158 | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS - The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder. | 11-01-2012 |
20120196803 | FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM - The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the invention may be used to treat any disease where increased neuronal survival or growth is desired, e.g., neurodegenerative diseases, such as Parkinson's disease or amyotrophic lateral sclerosis. Other diseases can be treated using the compounds include schizophrenia and depression. | 08-02-2012 |
20120141416 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF - The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases. | 06-07-2012 |
20120135914 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 05-31-2012 |
20120122798 | TREATMENT OF OVARIAN CANCER USING AN ANTICANCER AGENT CONJUGATED TO AN ANGIOPEP-2 ANALOG - Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2. | 05-17-2012 |
20120015876 | CONJUGATES OF GLP-1 AGONISTS AND USES THEREOF - The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes. | 01-19-2012 |
20110305750 | MEMBRANE TYPE-1 MATRIX METALLOPROTEIN INHIBITORS AND USES THEREOF - Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease. | 12-15-2011 |
20110288009 | LEPTIN AND LEPTIN ANALOG CONJUGATES AND USES THEREOF - The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a leptin, a leptin analog, or OB receptor agonist. The compounds of the invention can be used to treat any disease in which increased amounts of leptin are desired, such as metabolic diseases including obesity and diabetes. | 11-24-2011 |
20110171128 | APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases. | 07-14-2011 |
20110112036 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE - Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included. | 05-12-2011 |
20110039785 | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF - The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder. | 02-17-2011 |
20100297120 | APROTININ-LIKE POLYPEPTIDES FOR DELIVERING AGENTS CONJUGATED THERETO TO TISSUES - Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB. | 11-25-2010 |
20090082277 | Potentiation of anticancer agents - The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer. | 03-26-2009 |
20080299039 | Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases. | 12-04-2008 |